Key Sessions
Pall Thordarson
Scaling & Manufacturing Sustainable and Personalised RNA Therapeutics & Vaccines
UNSW
Day 2 - UTC+08:00
Day 2
- UTC+08:00
7:45am - 8:50am65 mins
Registration
8:50am - 9:00am10 mins
Keynote
RNA Leaders Welcome
9:00am - 9:45am45 mins
Keynote
Investment, Partnering & External Innovation - Catalyzing International Big Pharma & Investment with APAC Partnerships for the Next Wave of RNA Therapies
- Jenny Yang - Head of External Innovation Asia-Pacific, Novo Nordisk
- Soyoung Park - General Partner, 1004 Venture Partners
- Eddie Li - Director, Genetic Medicine, Eli Lilly
- Carl Firth - Partner, Panacea Ventures
9:45am - 10:30am45 mins
Keynote
Scaling & Manufacturing Sustainable and Personalised RNA Therapeutics & Vaccines
- Pall Thordarson - Director of the UNSW RNA Institute, UNSW
- Tim Mercer - Director, The University of Queensland
10:30am - 11:30am60 mins
Networking Power Hour
11:30am - 12:00pm30 mins
Scaling and Innovating mRNA products
Next-Generation mRNA Therapies
- Archa Fox - Director, Australian Centre for RNA Therapeutics in Cancer, RNA Innovation Foundry
12:00pm - 12:30pm30 mins
Scaling and Innovating mRNA products
Logic-Gated mRNA: Precision On-Off Switches for Cell-Type-Specific Therapies
- Sophia Lugo - CEO, Radar Therapeutics
12:30pm - 1:00pm30 mins
Scaling and Innovating mRNA products
Synthetic, enzymatically produced GMP grade DNA for production of mRNA Therapies and Vaccines
- Amy Walker - COO & EVP of Research and Business Development, 4Basebio
1:00pm - 2:15pm75 mins
Lunch
2:15pm - 2:45pm30 mins
Oligonucleotides Therapeutics- Targets, Innovation and Advancements
Thiomorpholino Oligonucleotide Biological Research
- Marvin Caruthers, PhD - Distinguished Professor, Biochemistry, University of Colorado
2:45pm - 3:15pm30 mins
Oligonucleotides Therapeutics- Targets, Innovation and Advancements
Chemistry, Design and Dynamics of Novel Splice Switching Antisense Oligonucleotides
- Rakesh Naduvile Veedu - Professor & Head Precision Nucleic Acid Therapeutics Group Co-Founder, ProGenis Pharmaceuticals (RNA therapeutics development) Founder, SynGenis Pty Ltd (RNA Manufacturing), Murdoch University
3:15pm - 3:45pm30 mins
Oligonucleotides Therapeutics- Targets, Innovation and Advancements
Development of exon skipping technology for the treatment of Duchenne muscular dystrophy
- Steve Wilton - Foundation Chair in Molecular Therapy, Murdoch University
3:45pm - 4:15pm30 mins
Afternoon Break
4:15pm - 5:15pm60 mins
RNA Leaders CEO Forum
RNA Leaders CEO Forum
5:15pm - 5:30pm15 mins
RNA Leaders CEO Forum
Closing Remarks
5:30pm - 5:35pm5 mins
Close of Congress
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。